BMEA
Biomea Fusion, Inc. [BMEA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BMEA Stock Summary
Top 10 Correlated ETFs
BMEA
Top 10 Correlated Stocks
BMEA
In the News
BMEA Financial details
Company Rating
-
Market Cap
459.51M
Income
-105.49M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
86
Optionable
No
Shortable
Yes
Earnings
07 Aug 2023
P/E
-5.29
Forward P/E
-
PEG
-0.59
P/S
-
P/B
5.83
P/C
-
P/FCF
-7.22
Quick Ratio
4.62
Current Ratio
4.74
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.27
EPS next Y
-
EPS next Q
-
EPS this Y
57.8%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.29%
-
-
-
-
SMA20
-50%
SMA50
-
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-81%
ROE
-77%
ROC
-1.04%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.125-43.69
52W High
-97.06%
52W Low
-84.19%
RSI
38
Rel Volume
0.55
Avg Volume
1.02M
Volume
561.92K
Perf Week
-4.17%
Perf Month
-20.44%
Perf Quarter
-35.79%
Perf Half Y
-1.94%
-
-
-
-
Beta
-1.05502
-
-
Volatility
0.02%, 0.24%
Prev Close
-2.69%
Price
1.265
Change
0.8%
Company Profile
- Volume Average 1.02M
- Market Capitalization 459.51M
- Employee 86
- CEO Mr. Thomas Andrew Butler
- Headquarters Redwood City,CA,US
- IPO Date 2021-04-16
-
Website
https://biomeafusion.com 
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
